Cargando…

Effects of aromatase inhibitor therapy on adiposity and cardiometabolic health in postmenopausal women: a controlled cohort extension study

PURPOSE: We previously demonstrated that 12 months of aromatase inhibitor (AI) treatment was not associated with a difference in body composition or other markers of cardiometabolic health when compared to controls. Here we report on the pre-planned extension of the study. The pre-specified primary...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheung, Yee-Ming M, Hoermann, Rudolf, Van, Karen, Wu, Damian, Healy, Jenny, Halim, Bella, Raval, Manjri, McGill, Maria, Al-Fiadh, Ali, Chao, Michael, White, Shane, Yeo, Belinda, Zajac, Jeffrey D, Grossmann, Mathis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503251/ https://www.ncbi.nlm.nih.gov/pubmed/37522858 http://dx.doi.org/10.1530/EC-23-0076

Ejemplares similares

Cardiometabolic Effects of Endocrine Treatment of Estrogen Receptor–Positive Early Breast Cancer
por: Cheung, Yee-Ming, et al.
Publicado: (2019)

Zoledronic acid does not affect insulin resistance in men receiving androgen deprivation therapy: a prespecified secondary analysis of a randomised controlled trial
por: Cheung, Ada S., et al.
Publicado: (2021)

Effects of testosterone treatment on body fat and lean mass in obese men on a hypocaloric diet: a randomised controlled trial
por: Ng Tang Fui, Mark, et al.
Publicado: (2016)

Hypothalamic-Pituitary-Thyroid Axis Set Point Alterations Are Associated With Body Composition in Androgen-Deprived Men
por: Hoermann, Rudolf, et al.
Publicado: (2017)

Tolvaptan versus fluid restriction in acutely hospitalised patients with moderate-profound hyponatraemia (TVFR-HypoNa): design and implementation of an open-label randomised trial
por: Warren, Annabelle M., et al.
Publicado: (2022)

Effect of testosterone treatment on bone remodelling markers and mineral density in obese dieting men in a randomized clinical trial
por: Ng Tang Fui, Mark, et al.
Publicado: (2018)

Androgen deprivation causes selective deficits in the biomechanical leg muscle function of men during walking: a prospective case–control study
por: Cheung, Ada S., et al.
Publicado: (2016)

Effect of Testosterone Treatment on Adipokines and Gut Hormones in Obese Men on a Hypocaloric Diet
por: Ng Tang Fui, Mark, et al.
Publicado: (2017)

Testicular volume and clinical correlates of hypothalamic–pituitary–testicular function: A cross-sectional study in obese men
por: Tang Fui, Mark Ng, et al.
Publicado: (2019)

Prevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: The BATMAN Trial
por: Lomax, Anna J., et al.
Publicado: (2013)

Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients
por: Bertelsen, Bjørn-Erik, et al.
Publicado: (2021)

Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update
por: Mokbel, Ramia, et al.
Publicado: (2006)

Clinical Utility of Aromatase Inhibitors as Adjuvant Treatment in Postmenopausal Early Breast Cancer
por: Loaiza-Bonilla, Arturo, et al.
Publicado: (2013)

Incidence of menopausal symptoms in postmenopausal breast cancer patients treated with aromatase inhibitors
por: Hong, Dongsheng, et al.
Publicado: (2017)

Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action
por: Cairns, Junmei, et al.
Publicado: (2020)

Association of adjuvant aromatase inhibitor with cataract risk in postmenopausal women with breast cancer
por: Chen, Han, et al.
Publicado: (2020)

Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Breast Cancer: A Network Meta-Analysis
por: Chen, Shanshan, et al.
Publicado: (2022)

Precautions for Patients Taking Aromatase Inhibitors
por: Heery, Mary, et al.
Publicado: (2020)

Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers.
por: Yates, R. A., et al.
Publicado: (1996)

Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women
por: Goss, Paul E, et al.
Publicado: (2007)

Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer
por: Gonnelli, Stefano, et al.
Publicado: (2008)

Ovarian mucinous adenocarcinoma with functioning stroma in postmenopausal women: aromatase and SF-1 expressions
por: Hattori, Yuka, et al.
Publicado: (2015)

Survival Benefit of Zoledronic Acid in Postmenopausal Breast Cancer Patients Receiving Aromatase Inhibitors
por: Ahn, Sung Gwe, et al.
Publicado: (2014)

Higher Insulin Resistance and Adiposity in Postmenopausal Women With Breast Cancer Treated With Aromatase Inhibitors
por: Gibb, Fraser W, et al.
Publicado: (2019)

Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions
por: Ligibel, Jennifer A, et al.
Publicado: (2005)

Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy
por: Derzko, C., et al.
Publicado: (2007)

Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers
por: Schuster, Eugene F., et al.
Publicado: (2023)

The Aromatase Gene (CYP19A1) Variants and Circulating Hepatocyte Growth Factor in Postmenopausal Women
por: Lin, Jennifer H., et al.
Publicado: (2012)

The role of hormones and aromatase inhibitors on breast tumor growth and general health in a postmenopausal mouse model
por: Arumugam, Arunkumar, et al.
Publicado: (2014)

Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer
por: Pfeiler, G, et al.
Publicado: (2013)

Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant
por: Kümler, Iben, et al.
Publicado: (2016)

Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer
por: Giles, Erin D., et al.
Publicado: (2018)

Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer
por: Martino, Gabriella, et al.
Publicado: (2020)

Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC
por: Young, Patricia A., et al.
Publicado: (2021)

The effect of exercise training on endothelial function in postmenopausal women with breast cancer under aromatase inhibitor therapy
por: Mayr, Barbara, et al.
Publicado: (2022)

Androidal Fat Dominates in Predicting Cardiometabolic Risk in Postmenopausal Women
por: Matvienko, O. A., et al.
Publicado: (2010)

Effect of Adherence to Physical Exercise on Cardiometabolic Profile in Postmenopausal Women
por: Bucciarelli, Valentina, et al.
Publicado: (2021)

SAT413 Feminising Gender Affirming Hormone Therapy Prolongs QTc Interval
por: Angus, Lachlan, et al.
Publicado: (2023)

Dexmethylphenidate-Induced Rhabdomyolysis by Interaction With Aromatase Inhibitor
por: Huang, Derrick, et al.
Publicado: (2022)

Measuring thyroid peroxidase antibodies on the day nulliparous women present for management of miscarriage: a descriptive cohort study
por: Grossmann, Mathis, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_slohdle7i2umn7ejsplmmcalg0